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ABSTRACT
Objectives: To evaluate risk factors associated with the local recurrence of invasive squamous cell vulvar cancer in patient 
group with tumor-free pathological margins.
Material and methods: This is a retrospective analysis of 47 patients who underwent surgical treatment at University 
Hospital Brno, the Czech Republic between 2007 and 2014. 24 patients were classified as IB stage and three as II stage. 
A further 20 patients representing stage III showed the metastatic involvement of regional lymph nodes. Seven prognostic 
factors were analyzed in relation to local tumour recurrence: tumour size, margin distance, depth of invasion, lymphovascular 
space involvement (LVSI), midline involvement, metastatic lymph nodes and FIGO stage. 
Results: All prognostic factors were found to be statistically significant with respect to the risk of local recurrence. The 
highest risk of local recurrence was observed for the depth of invasion > 5 mm (HR, 12.42 [95% CI; 3.44–44.84]) and for the 
presence of LVSI (HR, 10.83 [95% CI; 3.87–30.28]). The study also established a clear difference in the risk of local recurrence 
between patient groups with resection margin < 8 vs. ≥ 8 mm (HR, 4.91 [95% CI; 1.73–13.93; p = 0.003].
Conclusions: Tumour-free pathological margin of ≥ 8 mm is a major prognostic factor of local recurrence which can be 
influenced by the surgeon. A perfect knowledge of the extent of the disease prior to surgery supports adequately radical 
surgical trends. The emphasis is given on adequate radicality as well as on the reduction of overtreatment without worse-
ning prognosis by simultaneously preserving the quality of life.
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INTRODUCTION
Vulvar squamous cell carcinoma (VSCC) is a less frequen-
tly occurring tumour among predominantly older women. It 
accounts for 3–5% of all gynaecological malignancies, but its 
incidence has been steadily increasing over the past twenty 
years. Median age at vulvar cancer diagnosis is 68 years and 
the median age at death is 79 years [1]. Surgical treatment is 
a preferred treatment approach not only in the early stages 
but also in most locally advanced cases and recurrences 
[2, 3]. Surgical treatment strategies for the vulva and 
adjacent lymph nodes has changed considerably over the 
past two decades. Novel surgical approaches are primarily 
focused on the early stages of disease with a preference for 
broad local excision combined with sentinel node biopsy. 
Locally advanced findings are, from this perspective, more 
challenging and treatment results less satisfactory. The sur-
gical strategy in these cases generally includes vulvectomy 
with systematic bilateral inguinofemoral lymphadenectomy 
[3, 4]. In the case of extensive defects which cannot be solved 
by a simple suture, reconstruction surgery performed by 
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a reconstructive surgeon may be imperative [5, 6]. An alterna-
tive to this approach is the use of the concept of neoadjuvant 
chemotherapy with or without concomitant radiotherapy in 
patients with severe internal comorbidities [7, 8].
Approximately one-third of patients experience a recur-
rence of the disease, predominantly in the first two years 
following the end of primary therapy [9, 10]. A majority of re-
currences represent isolated local vulvar recurrences which 
may be curatively resolved by radical wide local excision 
[11, 12]. However, the regional recurrence of the disease in 
the groin is difficult to treat and is largely associated with 
poor prognosis [13, 14]. The management of retroperito-
neal and remote disease recurrence is based on symptom 
control, as radiotherapy and chemotherapy exhibit limited 
success rates [15].
Objectives
The aim of this retrospective study is to analyze risk 
factors associated with local recurrence in a group of VSCC 
patients classified as stages IB-IIIC according to the Inter-
national Federation of Gynecology and Obstetrics (FIGO), 
provided there are tumour-free pathological margins at 
first-line surgical therapy.
MATERIAL AND METHODS
This retrospective study includes 47 patients with inva-
sive VSCC classified as FIGO stages IB–IIIC who underwent 
primary surgery with tumour-free pathological margins be-
tween January 2007 and December 2014 at the Department 
of Gynecology and Obstetrics of the University Hospital Brno 
(Brno, Czech Republic). Patients with microinvasive carcino-
ma (FIGO stage IA) with the negative resection margins have 
an excellent prognosis, therefore we did not include them in 
the study. Based on biopsy results and local clinical findings, 
suitable imaging methods were employed before surgery in 
order to determine the expected stage of the disease and to 
exclude distant metastases. An ultrasound examination was 
generally used to evaluate possible malignant inguinofe-
moral lymphadenopathy while computer tomography was 
predominantly used to exclude pelvic lymphadenopathy 
and tumour dissemination above the pelvis. Scintigraphy 
was performed to exclude bone metastases and a PET/CT 
scan was employed when planning a large-scale excision 
with reconstruction. Only patients who were expected to 
complete primary staging surgery, i.e. patients without fixed 
inguinofemoral lymphadenopathy and with no suspicion of 
distant metastases, were included in the evaluation.
In all patients, the surgical procedure consisted of exci-
sion surgery on the vulva in combination with a surgical 
verification of regional lymph node status. Vulvar surgery 
was defined as a radical excision or vulvectomy, depending 
on the size of the tumoor and the coexistence of dystrophic 
and premalignant changes. Regional inguinofemoral lym-
phadenectomy was performed as unilateral or bilateral. 
In lateral tumours, only ipsilateral lymphadenectomy was 
performed. A unilateral tumour was defined as a lesion 
which does not cross the midline, with the medial margin 
of the tumour more than 10 mm from the midline struc-
tures. The utilized lymphadenectomy technique included 
systematic performance or sentinel node biopsy (SNB). SNB 
was performed in tumours smaller than 4 cm in case of 
negative clinical and ultrasound findings in the inguinofe-
moral lymphatic region; in case sentinel node was found 
to be positive, bilateral systemic lymphadenectomy was 
performed. Adjuvant radiotherapy for the vulva region was 
reported by patients with a resection margin of < 8 mm, 
a depth of invasion > 5 mm, a presence of lymphovascular 
space involvement (LVSI) and with locally advanced tumours 
infiltrating of surrounding organs. Adjuvant radiotherapy 
of the lumbar region (inguinofemoral and pelvic) was in-
dicated in case more than one regional node was involved 
or extracapsular spread was presented (irrespective of the 
number of affected nodes).
Information on age was reported by each patient while 
histotype and tumour grade were determined on the basis of 
the performed operation. Additionally collected information 
included tumour size, margin distance, depth of invasion, 
LVSI, midline involvement and metastatic inguinofemoral 
lymph nodes. The staging of the disease according to FIGO 
was determined, and risk factors for recurrence, disease-free 
survival (DFS), overall survival (OS) and mortality index due 
to disease progression were analyzed. All enrolled patients 
met the regular follow-up (range, 4–105 months) criterion.
Statistical analysis
Categorial variables were reported as absolute numbers 
and percentages and continuous variables as means ± SD 
or median (range) respectively. Associations between pro-
gnostic factors and recurrence were tested using the Spe-
arman correlation coefficient and the chi-squared test. The 
Cox proportional hazard ratio was assessed to estimate risk 
factors for recurrences. Differences in the distributions of 
patient characteristics were analyzed using the t-test and 
the Mann-Whitney test. DFS and OS were analyzed using the 
Kaplan-Meier test. Differences associated with p < 0.05 were 
considered significant. All analyses were performed using 
SAS version 9.4 (SAS Institute, Cary, NC, USA) and graphics 
were constructed using R version 3.2.1 (R Foundation for 
Statistical Computing, Vienna, Austria).
RESULTS
The analysis included a total of 47 patients with invasive 
VSCC. The youngest patient was 44, the oldest was 85 years 
old. All tumours included in the analysis were unifocal. When 
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evaluating the local tumour range on the vulva, the most 
common was T1b, encountered in 38 patients (80.8%), fol-
lowed by T2 in the remaining 9 patients (19.2%) where local 
infiltration spread from the vulva to the adjacent organs (the 
distal third of the urethra and vagina). A large tumour of at 
least 40 mm in the largest dimension occurred in 42.5% of 
all patients. The appropriate margins ≥ 8 mm, recommen-
ded by most existing studies, were achieved in 22 patients 
(46.8%), close margins (< 8 mm) were observed in 25 pa-
tients (53.2%), ranging from 0.15 to 7.0 mm. The depth of 
invasion > 5 mm occurred in 22 patients (46.8%) with a pre-
dominance of larger tumours and a mean of 51 mm (range, 
12–120 mm). LVSI was present in 25.5% of patients and was 
always associated with the presence of malignant inguino-
femoral lymphadenopathy with an average of 4.0 meta-
static nodes (range: 1–10 metastatic nodes). The tumours 
were predominantly involved in the midline area (76.6%), 
while the most frequently occurring grade was moderately 
differentiated. A progression to regional lymph nodes was 
Table 1. Patient and tumor characteristics
Patient and tumor characteristics N %
Age (years)
Median (range) 70.0 (44.0–85.0)
Tumor size (mm)
Median (range)
< 40 mm
≥ 40 mm
35.0 (6.0–120.0)
27
20
57.4
42.6
Margin distance (mm)
Median (range)
< 8 mm
≥ 8 mm
7.0 (0.15–20.0)
25
22
53.2
46.8
Depth of invasion (mm)
Median (range)
≤ 5 mm
> 5 mm
5.0 (0.5–12.0)
25
22
53.2
46.8
LVSIa
Yes
No
12
35
25.5
74.5
Involvement of midline
Involved
Not involved
36
11
76.6
23.4
Grade
Grade 1
Grade 2
Grade 3
7
31
9
14.9
66.0
19.1
Metastatic lymph nodes
No metastases
Ipsilateral
Bilateral
27
14
6
57.4
29.8
12.8
FIGOb stage
I
II
III
24
3
20
51.1
6.3
42.6
aLVSI — Lymphovascular Space Invasion; bFIGO — International Federation of 
Gynecology and Obstetrics
Table 2. Treatment characteristics
Treatment No. patients %
Surgical treatment only 15 31.9
Radical excision with lymphadectomy
ipsilateral
bilateral
7
2
14.9
4.3
Vulvectomy with lymphadenectomy
ipsilateral
bilateral
1
5
2.1
10.6
Surgical treatment with radiotherapy 32 68.1
Radical excision with 
lymphadenectomy
ipsilateral
bilateral
0
7
0.0
14.9
Vulvectomy with lymphadenectomy
ipsilateral
bilateral
1
24
2.1
51.1
established in 20 patients (42.5%), with six patients pre-
sented with bilateral involvement. These 20 patients were 
classified as stage III according to FIGO (five patients each 
as stages IIIA and IIIB, 10 as stage IIIC). Stage IB, observed in 
24 patients, was most common (Tab. 1).
Table 2 provides an overview of the performed surgical 
procedures. A total of 15 patients (31.9%) were subjected 
to primary surgery with no need for adjuvant therapy, with 
a predominance of radical excision, performed in the case 
of 9 patients (60.0%) in this subgroup. This subgroup featu-
red an almost identical proportion of ipsilateral and bilateral 
lymphadenectomy. A total of 32 patients (68.1%) underwent 
combined vulvar and regional node surgery followed by ad-
juvant radiotherapy. This subgroup most frequently inclu-
ded patients subjected to a combination of vulvectomy with 
lymphadenectomy (25 patients), the lymphadenectomy was 
performed as unilateral in only one case. In eight patients, sup-
plementary reconstruction surgery of the vulva with bilateral 
use of the skin lobes was necessary for overlap of the defect. 
All 32 patients underwent adjuvant radiotherapy in the area 
of the vulva; nodal radiotherapy was performed in 20 patients.
During the follow-up period, 21 recurrences (44.7%) were 
observed, with the disease recurring in 76.2% of patients du-
ring the first two years after primary therapy. Table 3 provides 
an overview of the anatomical localization of recurrences, 
depending on analyzed prognostic factors. In 13 patients, the 
recurrence was observed in the vulvar region; the median re-
currence period was 16 months (range, 6–82 months). Of the 
patients with local recurrence, 53.8% were primarily enrol-
led at advanced stage III with the metastatic involvement 
of regional lymph nodes. Three cases of regional relapse 
in the groin were preceded by systematic inguinofemoral 
lymphadenectomy, and only one patient of them had a ne-
gative surgical staging of the lymph nodes during primary 
427
Lubos Minar et al., Recurrence of vulvar cancer
www. journals.viamedica.pl/ginekologia_polska
surgery. The median rate of regional recurrence period was 
12 months (range, 10–15 months). In five patients with pri-
mary metastatic regional lymph nodes, distant metastases 
appeared, always as the pelvic lymphadenopathy, which was 
combined with pulmonary involvement in two cases and 
with bone metastases and brain involvement in one case 
respectively. The median occurrence of distant recurrences 
was 6 months (range, 3–10 months). We recorded the deaths 
of 19 patients, two of whom died without recurrence of other 
causes; the mortality index for the analyzed group was 40.4%. 
Four patients with surgically treated local recurrence are still 
alive and 24 patients live without recurrence.
During the follow-up period (range, 4–118 months), 
we observed a mean DFS of 66.7 + 6.5 months (95% CI; 
54.0–79.5) (Fig. 1) and a mean OS of 69.7 + 6.2 months 
(95% CI; 57.6–81.8) (Fig. 2). 
The univariate analysis of local vulvar recurrence es-
tablished a statistical significance in all prognostic factors 
analyzed at p < 0.05. By quantifying the risk of recurrence risk 
using the Cox regression model, we found the highest risk of 
local relapse in patients exhibiting invasion depth > 5 mm 
compared to invasion depth ≤ 5 mm, HR 12.42 (95% CI, 
3.44–44.84), and in the patients with LVSI compared to those 
without LVSI, HR 10.83 (95% CI; 3.87–30.28) (Tab. 4).
Table 3. Risk factors for vulvar cancer recurrence 
Risk factor Vulvar recurrence/No. patients (%)
Groin recurrence/
No. patients (%)
Distant recurrence/
No. patients (%)
Tumor size 
< 40 mm
≥ 40 mm
7 /27 (25.9)
6/20 (30.0)
1/27 (3.7)
2/20 (10.0)
1/27 (3.7)
4/20 (20.0)
Margin distance 
< 8 mm
≥ 8 mm
9/25 (36.0)
4/22 (18.2)
2/25 (8.0)
1/22 (4.5)
5/25 (20.0)
0/22 (0.0)
Depth of invasion
≤ 5 mm
> 5 mm
4/25 (16.0)
9/22 (40.9)
0/25 (0.0)
3/22 (13.6)
0/25 (0.0)
5/22 (22.7)
LVSIa
Yes
No
5/12 (41.7)
8/35 (22.9)
2/12 (16.7)
1/35 (2.9)
4/12 (33.3)
1/35 (2.9)
Involvement of midline
Involved
Not involved
13/36 (36.1)
0/11 (0.0)
2/36 (5.6)
1/11 (7.7)
5/36 (13.9)
0/11 (0.0)
Metastatic lymph nodes
No metastases
Metastases
6/27 (22.2)
7/20 (35.0)
1/27 (3.7)
2/20 (10.0)
0/27 (0.0)
5/20 (25.0)
FIGOb stage
I + II
III
6/27 (22.2)
7/20 (35.0)
1/27 (3.7)
2/20 (10.0)
0/27 (0.0)
5/20 (25.0)
aLVSI — Lymphovascular Space Invasion; bFIGO — International Federation of Gynecology and Obstetrics
Figure 1. Kaplan-Meier estimate of survival function (DFS) Figure 2. Kaplan-Meier estimate of survival function (OS)
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Table 4. Risk factors predicting local recurrence
Risk factor HRc (95% CI) p
Tumor size 
(≥ 40 mm vs. < 40 mm) 2.80 (1.12–6.99) 0.027
Margin distance 
(< 8 mm vs. ≥ 8 mm) 4.91 (1.73–13.93) 0.003
Depth of invasion
(> 5 mm vs. ≤ 5 mm) 12.42 (3.44–44.84) < 0.001
LVSIa
(yes vs. no) 10.83 (3.87–30.28) < 0.001
Involvement of midline
(involved vs. not involved) 7.63 (1.02–57.12) 0.048
Metastatic lymph nodes
(metastases vs. no metastases) 9.64 (3.03–30.69) < 0.001
FIGOb stage
(III vs. I + II) 9.64 (3.03–30.69) < 0.001
aLVSI — Lymphovascular Space Invasion; bFIGO — International Federation of 
Gynecology and Obstetrics; cHR — Cox proportional hazard ratio
Table 5. Risk factors of local recurrence — impact of the time interval to recurrence
Risk factor Recurrence ≤ 2 yearsNo./8 patients (%)
Recurrence > 2 years
No./5 patients (%) p
c
Tumor size (≥ 40 mm) 4/8 (50.0) 2/5 (40.0) 0.724
Margin distance (< 8 mm) 7/8 (87.5) 2/5 (40.0) 0.070
Depth of invasion (> 5 mm) 6/8 (75.0) 1/5 (20.0) 0.047
LVSIa 4/8 (50.0) 1/5 (20.0) 0.268
Involvement of midline 8/8 (100.0) 5/5 (100.0) 0.991
Metastatic lymph nodes 6/8 (75.0) 1/5 (20.0) 0.047
FIGOb stage III 6/8 (75.0) 1/5 (20.0) 0.047
aLVSI — Lymphovascular Space Invasion; bFIGO — International Federation of Gynecology and Obstetrics; cmaximum likelihood estimation method
Table 6. Associations between continuous variables
Variables Age Tumor size Margin distance
Tumor size pa = 0.051 — —
Margin distance pa = 0.040 pa = 0.006 —
Depth of invasion pa = 0.096 pa = 0.001 pa = 0.006
aSpearman correlation coefficient
Table 7. Asociations between categorial variables
Variables LVSIb Involvement of midline
Metastatic 
lymph 
nodes
Involvement of 
midline p
c = 0.807 — —
Metastatic lymph 
nodes p
c < 0.001 pc = 0.129 —
FIGOa stage pc < 0.001 pc = 0.129 pc < 0.001
aFIGO — International Federation of Gynecology and Obstetrics; bLVSI 
— Lymphovascular Space Invasion; cchi-squared test
In the next part of the analysis, we focused on the com-
parison of the risk of recurrence stratified by the time interval 
of recurrence. Borderline statistical significance for early 
recurrence in the first two years compared to late recurrence 
was found to be associated with depth of invasion (> 5 mm), 
metastatic lymph nodes and advanced FIGO stages (Tab. 5). 
When the associations between continuous variables (age, 
tumour size, margin distance, depth of invasion) were tested, 
statistical significance was not established between age and 
depth of the invasion, the borderline significant association 
was identified between the age and size of the tumour, other 
correlations were statistically significant (Tab. 6). Statistically 
significant associations between LVSI and metastatic lymph 
nodes, LVSI and FIGO stage, metastatic lymph nodes and 
FIGO stage respectively were observed when testing the 
associations between categorical variables (Tab. 7). When 
testing differences between distributions of continuous 
variables across categories, no statistically significant as-
sociation between only age and midline involvement; and 
Table 8. Differences in the distribution of continuous variables 
across categories 
Variables LVSIc Involvementof midline FIGO
d stage
Age pa = 0.012 pa = 0.788 pa = 0.020 
Tumor size pa = 0.004 pa = 0.006 pa < 0.001
Margin distance pb = 0.052 pb = 0.028 pb = 0.001
Depth of invasion pb < 0.001 pb = 0.072 pa < 0.001
at-test; bMann-Whitney test; cFIGO — International Federation of Gynecology 
and Obstetrics; dLVSI — Lymphovascular Space Invasion
depth of the invasion and midline involvement respectively 
was not observed. The borderline significant association was 
determined between margin distance and LVSI (Table 8). Due 
to the limited number of regional and remote recurrences, 
no analysis of their prognostic factors was conducted.
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DISCUSSION
Primary surgery is a preferred therapeutic approach for 
VSCC in case no distant metastases are present. The progno-
sis of primarily operated patients is strictly dependent on the 
metastatic involvement of regional lymph nodes, which is 
strongly associated with the risk of relapse and aggravated 
survival. This was demonstrated in our group of patients, 
where recurrence (regardless of its localization) occurred in 
70% of patients with primary metastatic lymphadenopathy. 
Half of the recurrences in these patients occurred in the 
inguinal area or pelvic lymph nodes, which is consistent 
with the literature [16–18]. Most prevalently, the patients 
with primary extracapsular nodal involvement presented 
with most frequent recurrence (90%) despite adjuvant ra-
diotherapy. In spite of this, surgical treatment followed by 
radiotherapy is more efficient and preferable to radiotherapy 
alone [3]. In case of suspected metastatic involvement of the 
groin nodes, a biopsy should be performed. The optimal 
management of these cases — inguinofemoral lymphade-
nectomy or groin node debulking — has not been defined 
yet [3, 19]. The exclusion of the presence of disease in the 
pelvis using PET/CT or PET/MRI is important to determine 
a rational treatment strategy [20, 21]. In case a patient’s 
condition is suitable, pelvic debulking may be considered 
as an option despite the fact that pelvic disease is already 
considered a distant metastatic involvement [3].
In case of regional lymph nodes are found to be negati-
ve, a set of clinical and histopathological parameters which 
may affect disease recurrence must be considered. Due to 
the limited number of regional and remote recurrences in 
our study, we statistically analyze possible prognostic factors 
only for the risk of local recurrence. All seven analyzed pro-
gnostic factors were revealed to be statistically significant 
in this analysis; midline involvement achieved borderline 
statistical significance, likely due to more radical surgical 
treatment in patients with this risk factor. The highest risk of 
local recurrence occurred in coincidence with the presence 
of a deep invasion of > 5 mm and LVSI (12× or 10× higher 
respectively). Other intergroup analyses revealed the stati-
stically significant associations of some continuous (tumour 
size, margin distance, depth of invasion) and categorical 
variables (LVSI, metastatic lymph nodes).
Although the total number of recurrences (local, regio-
nal, remote) reporting in our study is relatively high (44.7%), 
disease recurrence occurred in a quarter of the patients 
after more than two years from the end of the primary 
treatment. The proportion of local recurrences among the 
total number of recurrences is 62%; this correlates with re-
cent sources which report rates in excess of 50% [10, 16, 22]. 
The proportion of local relapses recurring after more 
than two years of follow-up was almost 40% in our study. 
This is a substantial challenge, eliciting a discussion of the 
VSCC local recurrence definition, in the frame of which two 
factors should be considered. First, it is recurrence interval, 
second, the distance between localization of primary tu-
mour and recurrence. As most recurrence cases take place 
during the first two years, some authors have suggested that 
late recurrences may, in fact, constitute de novo tumours 
[23, 24]. Our analysis found borderline statistical significance 
for an early risk of local recurrence (up to two years) in three 
prognostic factors (depth of invasion > 5 mm, metastatic 
lymph nodes, FIGO III stage). To facilitate the discussion and 
differentiate a real local recurrence from de novo tumour, 
the detailed documentation, including an image or clinical 
plot, appears as crucial [3, 23, 24].
FIGO I-II stages represent in our study almost 58% of 
all cases, which corresponds to the current distribution of 
the early stages of the disease in the population of Czech 
women [25]. 
Furthermore, 20 patients with stage III were included 
in the analysis. The inclusion of advanced-stage patients 
helps to validate the relationship between prognostic fac-
tors and risk of local recurrence. Thus, these results are not 
only limited to those with early-stage cancers but can be 
generalized to the more advanced tumours in that is also 
important to obtain adequate margins in advanced cancers 
for palliative surgical care to provide symptomatic relief and 
prevent local recurrence.
68% of our patients received adjuvant radiotherapy 
to the vulva, therefore the group can seem inconsistent 
from this perspective. However, radiotherapy for the vulva 
region was recommended for patients with a clear indication 
(a resection margin of < 8 mm, a depth of invasion > 5 mm, 
a presence of LVSI, locally advanced tumours infiltrating 
of surrounding organs). Moreover, the incidence of local, 
regional or distant relapses was not effectively influenced 
by adjuvant radiotherapy after primary surgery in our study. 
This can be documented by the fact that out of 13 local 
vulvar recurrences, only one case did not receive adjuvant 
treatment. In another eight relapses (three in the groin and 
five in pelvic lymph nodes) adjuvant radiotherapy was per-
formed in these anatomical sites in seven patients. Further 
investigations and new studies dealing with the effect of 
adjuvant and neoadjuvant radiotherapy are the next logical 
steps in the assessment of this modality of treatment. 
To achieve tumour-free margins is the major prognostic 
factor influenced by the surgeon. Our analysis reveals the 
statistical significance of adequate surgical margins (≥ 8 mm) 
in the reduction of risk of recurrence. In the case of close 
resection margins, no statistically significant difference in 
the increased risk of early local recurrence (up to two years) 
was observed compared to relapse after more than two 
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years. A recent expert opinion states that the free-resection 
margin should be at least 1 cm [3]. Concurrently, however, 
it is stressed that it is acceptable to consider less wide mar-
gins in case the tumour lies close to midline structures and 
preserving their function is desired [3]. The results of studies 
comparing the association of the width of free-resection 
margins and the rate of local recurrence are inconclusive 
and this topic remains the most controversial point in the 
surgical treatment of vulvar carcinoma [26–30]. Therefore, 
it is necessary to focus on new histopathological, genetic 
and epigenetic factors. Actual sources state the increased 
risk of recurrence based on increased tumour aggression 
in association with the presence of perineural invasion or 
epithelial-mesenchymal transition [31, 32]. Increased risk of 
local recurrence is also characterized by HPV tumour negati-
vity in conjunction with differentiated VIN, lichen sclerosus 
and genetic alterations such as TP53 mutations [33, 34].
CONCLUSIONS
Based on the results of our study, the major prognostic 
factor of local VSCC recurrence influenced by the surgeon is 
represented by tumour-free pathological margins ≥ 8 mm. 
The achievement of such margins is an important prerequ-
isite for reducing the risk of local recurrence while respec-
ting the current trend of less radical locoregional surgery. 
A perfect knowledge of the extent of the disease prior to 
surgery as well as the definition of new molecular progno-
stic parameters should be to support adequately radical 
trends in the current surgical treatment of vulvar cancer. 
The emphasis is given on adequate radicality as well as on 
reduction of overtreatment without worsening prognosis 
by simultaneously preserving the quality of life. 
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